Imugene Ltd (ASX: IMU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imugene Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $342.16 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 7.57 billion
Earnings per share -0.021
Dividend per share N/A
Year To Date Return -51.82%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Imugene Ltd (ASX: IMU)
    Latest News

    A man clenches his fists in excitement as gold coins fall from the sky.
    Share Gainers

    Why Imugene, Neuren, Sigma, and Smartgroup shares are charging higher

    These shares are ending the week on a high. But why? Let's find out.

    Read more »

    A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
    Share Gainers

    Why Core Lithium, Imugene, Lifestyle Communities, and Mineral Resources shares are charging higher

    These shares are having a good session. What's going on?

    Read more »

    A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
    Share Market News

    Guess which ASX 300 stock is jumping 11% on big news

    Big news is giving this stock an even bigger lift on Tuesday. What's happening?

    Read more »

    Shot of a scientist using a computer while conducting research in a laboratory.
    Healthcare Shares

    2 All Ords ASX healthcare shares making BIG moves on quarterly updates

    These two ASX healthcare companies are seeing heavy trading on Thursday.

    Read more »

    A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
    Share Fallers

    Why AGL, Imugene, Star, and Woolworths shares are dropping today

    These shares are dropping on Thursday. Let's see why investors are selling them.

    Read more »

    Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
    Share Gainers

    Why Appen, Cettire, DroneShield, and Imugene shares are racing higher

    These shares are starting the week in style. But why?

    Read more »

    a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
    Healthcare Shares

    Why this ASX All Ords stock is soaring 30% on Monday

    This stock is starting the week with a bang. But why?

    Read more »

    A man wearing glasses and a white t-shirt pumps his fists in the air looking excited and happy about the rising OBX share price
    Share Gainers

    Why Catalyst Metals, Imugene, Red 5, and Telstra shares are pushing higher today

    These shares are outperforming on Wednesday. But why?

    Read more »

    A women cheers with clenched fists having read some good news on her laptop.
    Share Gainers

    2 ASX shares roaring higher on big news

    Investors are pleased with these announcements. Let's find out why.

    Read more »

    Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
    Healthcare Shares

    3 ASX healthcare shares outperforming on quarterly updates

    These stocks are charging ahead on an otherwise lacklustre trading day.

    Read more »

    medical asx share price represented by doctor giving thumbs up
    Healthcare Shares

    Broker says this ASX biotech stock could almost double in value

    Bell Potter is feeling very bullish about this risky stock.

    Read more »

    A man clenches his fists in excitement as gold coins fall from the sky.
    Share Gainers

    Why Imugene, Liontown, Pointsbet, and Regis Resources shares are storming higher

    These ASX shares are having a great session. But why?

    Read more »

    Frequently Asked Questions

    Imugene does not pay dividends at this stage. 

    Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.

    IMU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Imugene Ltd

    Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.

    The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.

    The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu. 

    Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.

    IMU Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    08 Nov 2024 $0.05 $0.00 0.00% 19,675,024 $0.05 $0.05 $0.05
    07 Nov 2024 $0.05 $0.00 0.00% 9,482,751 $0.05 $0.05 $0.04
    06 Nov 2024 $0.05 $0.00 0.00% 19,428,279 $0.05 $0.05 $0.04
    05 Nov 2024 $0.05 $0.00 0.00% 20,445,375 $0.05 $0.05 $0.05
    04 Nov 2024 $0.04 $0.00 0.00% 7,968,778 $0.05 $0.05 $0.04
    01 Nov 2024 $0.05 $0.00 0.00% 16,769,572 $0.04 $0.05 $0.04
    31 Oct 2024 $0.04 $0.00 0.00% 47,858,314 $0.05 $0.05 $0.04
    30 Oct 2024 $0.05 $0.00 0.00% 9,762,599 $0.05 $0.05 $0.05
    29 Oct 2024 $0.05 $0.00 0.00% 29,436,994 $0.05 $0.05 $0.05
    28 Oct 2024 $0.05 $0.00 0.00% 5,733,798 $0.05 $0.05 $0.05
    25 Oct 2024 $0.05 $0.00 0.00% 13,324,228 $0.05 $0.05 $0.05
    24 Oct 2024 $0.05 $0.00 0.00% 10,740,305 $0.05 $0.05 $0.05
    23 Oct 2024 $0.05 $0.00 0.00% 14,787,054 $0.05 $0.05 $0.05
    22 Oct 2024 $0.05 $0.00 0.00% 6,721,583 $0.05 $0.05 $0.05
    21 Oct 2024 $0.05 $0.00 0.00% 11,340,232 $0.05 $0.05 $0.05
    18 Oct 2024 $0.05 $0.00 0.00% 10,660,723 $0.05 $0.05 $0.05
    17 Oct 2024 $0.05 $0.00 0.00% 8,542,351 $0.05 $0.05 $0.05
    16 Oct 2024 $0.05 $0.00 0.00% 18,373,903 $0.05 $0.05 $0.05
    15 Oct 2024 $0.05 $0.00 0.00% 21,177,715 $0.05 $0.05 $0.05
    14 Oct 2024 $0.05 $0.00 0.00% 35,095,628 $0.05 $0.06 $0.05
    11 Oct 2024 $0.05 $0.00 0.00% 3,692,150 $0.05 $0.05 $0.05
    10 Oct 2024 $0.05 $0.00 0.00% 11,930,066 $0.05 $0.05 $0.05

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    01 Jul 2024 Leslie (Mi Ok) Chong Transfer 1,500,000 $82,500
    As advised by the company. Transfer from direct to indirect holding
    01 Jul 2024 Leslie (Mi Ok) Chong Buy 5,793,750 $318,656
    Conversion of securities.
    01 Jul 2024 Leslie (Mi Ok) Chong Exercise 5,793,750 $318,656
    Conversion of securities. 17,381,250 RIGHTS
    01 Jul 2024 Leslie (Mi Ok) Chong Transfer 1,500,000 $82,500
    As advised by the company. Transfer from direct to indirect holding
    01 Jul 2024 Paul Hopper Exercise 975,375 $53,645
    Conversion of securities. 2,926,125 PERFORMANCE RIGHTS AWARD
    01 Jul 2024 Paul Hopper Issued 975,375 $53,645
    Conversion of securities.
    01 Jul 2024 Lesley Russell Issued 250,000 $13,750
    Conversion of securities.
    01 Jul 2024 Lesley Russell Exercise 250,000 $13,750
    Conversion of securities. 750,000 - Restricted Stock Units
    01 Jul 2024 Jens Eckstein Exercise 250,000 $13,750
    Conversion of securities. 750,000 RSU
    01 Jul 2024 Jens Eckstein Issued 250,000 $13,750
    Conversion of securities.
    01 Jul 2024 Jakob Dupont Issued 250,000 $13,750
    Conversion of securities.
    01 Jul 2024 Jakob Dupont Exercise 250,000 $13,750
    Conversion of securities. 750,000 - Restricted Stock Units
    01 Jul 2024 Kim Drapkin Exercise 250,000 $13,750
    Conversion of securities. 750,000 - Restricted Stock Units
    01 Jul 2024 Kim Drapkin Issued 250,000 $13,750
    Conversion of securities. As per announcement on 08-07-2024
    19 Apr 2024 Paul Hopper Sell 5,242,277 $381,113
    On-market trade.
    18 Apr 2024 Paul Hopper Sell 4,500,000 $363,600
    On-market trade.
    17 Apr 2024 Paul Hopper Sell 4,380,952 $365,285
    On-market trade.
    01 Feb 2024 Paul Hopper Issued 110,790,024 $1,717,245
    Issue of securities. Subject to release from escrow, as per announcement on 01-02-2024
    01 Feb 2024 Paul Hopper Issued 1,381,422 $21,412
    Issue of securities. Subject to release from escrow, as per announecment on 01-02-2024
    01 Feb 2024 Paul Hopper Transfer 10,000,000 $1,000,000
    As advised by the company. Transfer of shares for nil
    consideration.
    12 Jan 2024 Leslie (Mi Ok) Chong Issued 23,175,000 $2,781,000
    Issue of securities. 23,175,000 - Performance Rights
    12 Jan 2024 Paul Hopper Issued 3,901,500 $468,180
    Issue of securities. 3,901,500 - Performance Rights
    12 Jan 2024 Lesley Russell Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs
    12 Jan 2024 Jakob Dupont Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs
    12 Jan 2024 Jens Eckstein Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs
    12 Jan 2024 Kim Drapkin Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Leslie (Mi Ok) Chong Chief Executive OfficerManaging Director Nov 2016
    Ms Chong joined the Group from the leading oncology clinical development company, Genentech (a member of the Roche family), where she was a Senior Clinical Program Lead at the head office in San Francisco. She has over 25 years of experience in leading clinical and department development in oncology. In November 2016, Former directorships in last three years - Cure Brain Cancer Foundation (non-profit organisation), until 11 April 2023.
    Mr Paul Alex Hopper Executive ChairmanExecutive Director Dec 2013
    Mr Hopper has over 20 years of experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered therapeutic areas with emphasis on immunotherapy. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States. Former directorships in last three years include Scopus BioPharma Inc (NASDAQ: SCPS), until 18 May 2022.
    Dr Lesley Russell Non-Executive Director Apr 2019
    Dr Russell is a haematologist/oncologist and has over 25 years of experience and leadership in the international pharmaceutical field as a Chief Medical Officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology and has had new drug approvals with FDA and European Medicines Agency. Dr Russell has experience as a director of NASDAQ listed pharmaceutical companies. She is a member of the Royal College of Physicians UK. Other current directorships - Enanta Pharmaceuticals (NASDAQ: ENTA), since 22 November 2016. Dr Russell is member of Risk Committee.
    Dr Jens Eckstein Non-Executive Director May 2019
    Dr Eckstein has more than 20 years of venture capital experience in the biopharmaceutical industry and 10 years of operational experience in drug discovery and development. He is a Kauffman Fellow and a mentor for lifescience entrepreneurs and start-up teams in the area of innovative lifescience and healthcare information technology companies. Before joining Apollo Ventures, Dr Eckstein served as president of SR One for eight years. He is also co-founder and managing director of Action Potential Venture Capital. Previously, he was a general partner at TVM Capital. He is member of Risk Committee.
    Dr Jakob Dupont Non-Executive Director Sep 2022
    Dr Dupont is an industry and drug development expert with more than 20 years of experience specialising in oncology and other therapeutic areas. Dr Dupont is currently the Executive Venture Partner at Sofinnova Investments. Dr Dupont's experience includes NASDAQ listed Atara Biotherapeutics (NASDAQ: ATRA), where he oversaw all research and development, including three clinical stage programs spanning Phase 1 through to Phase 3, and preclinical programs. Other current directorships include Pyxis Oncology (NASDAQ: PYXS); Avenzo Therapeutics and Flagship Pioneering (Scientific Advisory Board). Former directorships in last three years - Apexigen (NASDAQ: APGN) until August 2023. Dr Dupont is member of the Risk Committee.
    Ms Kim Drapkin Non-Executive Director Jun 2023
    Ms Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. In addition to Imugene, Ms Drapkin currently serves on the board of directors at Acumen Pharmaceuticals (NASDAQ: ABOS) where she chairs the audit committee and is a member of the compensation committee and LENZ Therapeutics (NASDAQ: LENZ) where she is a member of the compensation and governance committees. Recently, Ms Drapkin was CEO and a board member at Graphite Bio where she led the strategic alternatives process culminating in a reverse merger with LENZ Therapeutics. Prior to that, Ms Drapkin was CFO at Jounce Therapeutics since its inception, playing a role in building Jounce's financial infrastructure. Prior to joining Jounce, Ms Drapkin owned a financial consulting firm where she served as the interim chief financial officer for early stage biotechnology companies. Previously, Ms Drapkin was chief financial officer at EPIX Pharmaceuticals. Prior to EPIX, Ms Drapkin spent ten years in roles of increasing responsibility within the finance organisation at Millennium Pharmaceuticals. Ms Drapkin began her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP. Other current directorships are held with Acumen Pharmaceuticals (NASDAQ: ABOS); LENZ Therapuetics (NASDAQ: LENZ). Former directorships in last three years - Yumanity Therapeutics (NASDAQ: YMTX); Proteostasis Therapeutics (NASDAQ: PTI). She is chair of risk committee.
    Mr Michael (Mike) Tonroe Chief Financial OfficerCompany Secretary Mar 2023
    -
    Monil Shah Chief Business Officer
    -
    Mike Tonroe Chief Financial Officer
    -
    Michael (Mike) Tonroe Chief Financial OfficerCompany Secretary
    -
    Paul Woodard Chief Medical Officer
    -
    Bradley Glover Chief Operating Officer
    -
    Nicholas Ede Chief Technology Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Paul Hopper 409,071,906 5.57%
    JP Morgan 283,996,697 3.86%
    Citicorp Nominees Pty Limited 266,813,810 3.63%
    Mann Family 265,582,609 3.61%
    HSBC Custody Nominees (Australia) Limited i 213,532,203 2.91%
    Dr Nicolas Smith 118,000,000 1.61%
    Netwealth Investments Limited <Wrap Ser Vices A/C> 85,488,611 1.16%
    Mi Ok Chong 78,416,666 1.07%
    BNP Paribas Noms Pty Ltd 70,407,583 0.96%
    National Nominees Pty Ltd 60,113,645 0.82%
    UBS Nominees Pty Ltd 50,328,041 0.68%
    BNP Paribas Noms Pty Ltd <Ib Au Noms Retail Client> 48,979,324 0.67%
    HSBC Custody Nominees (Australia) Limited ii 29,079,510 0.40%
    Mr Phillip Wood 25,480,000 0.35%
    Sve Capital Pty Ltd <Strategic Vision Unit A/C> 23,000,000 0.31%
    Dr Yuman Fong 22,379,032 0.30%
    Dr Jen Eckstein 20,738,095 0.28%
    Dr Lesley Russell 20,238,095 0.28%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 20,230,709 0.28%
    Mr Scott Spencer Pappin & Mrs Tracey Lee Pappin <Pappin Super Fund A/C> 20,000,000 0.27%
    Jem Investment Fund Holdings Pty Ltd <Jem Invest Fund Family A/C> 20,000,000 0.27%

    Profile

    since

    Note